Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of Alberta, Edmonton, AB, Canada.
Department of Laboratory Medicine and Pathology, University of Alberta, University of Alberta Hospital, Edmonton, AB, Canada.
Cancer Biomark. 2019;24(2):141-151. doi: 10.3233/CBM-182106.
The role of molecular biomarkers in oropharyngeal squamous cell carcinoma (OPSCC) has recently been increasingly recognized. There is conflicting evidence in the literature with regards to the prognostic value of p53 and Bcl-xL.
The purpose of this study was to investigate the association between p53 and Bcl-xL expression profiles and survival outcomes in OPSCC.
Patients diagnosed with OPSCC and treated with curative intent between 1998 and 2009 were included in the study. Patient demographics, disease, treatment, and oncologic outcomes were collected prospectively. A tissue microarray (TMA) from patients' biopsies or surgical specimens was retrospectively constructed. The expression levels of p53, Bcl-xL, and p16 were digitally quantified and correlated to patient survival outcomes.
One hundred and sixty-six patients were included (mean age 56.7 years; standard deviation (SD) ± 10.0; 78% male). High expression of Bcl-xL (p= 0.04) was significantly associated with nodal disease at presentation, and decreased overall survival (OS) (p= 0.04). Combined expression of low Bcl-xL and low p53 conferred a survival advantage in non-smokers (p= 0.04). Multivariate analysis supported smoking and p16 status as independent prognosticators for OS.
This study suggests that biomarker profiling using Bcl-xL and p53 levels may be of prognostic value in select patients with OPSCC.
分子生物标志物在口咽鳞状细胞癌（OPSCC）中的作用最近得到了越来越多的认可。文献中关于 p53 和 Bcl-xL 的预后价值存在相互矛盾的证据。
本研究旨在探讨 p53 和 Bcl-xL 表达谱与 OPSCC 生存结局之间的关系。
本研究纳入了 1998 年至 2009 年间接受根治性治疗的 OPSCC 患者。前瞻性收集患者的人口统计学、疾病、治疗和肿瘤学结局数据。回顾性构建患者活检或手术标本的组织微阵列（TMA）。p53、Bcl-xL 和 p16 的表达水平进行数字化定量，并与患者的生存结局相关联。
本研究共纳入 166 例患者（平均年龄 56.7 岁；标准差 ± 10.0；78%为男性）。Bcl-xL 高表达（p=0.04）与初诊时的淋巴结疾病显著相关，并与总生存（OS）降低相关（p=0.04）。非吸烟者中低 Bcl-xL 和低 p53 联合表达具有生存优势（p=0.04）。多变量分析支持吸烟和 p16 状态是 OS 的独立预后因素。
本研究表明，使用 Bcl-xL 和 p53 水平进行生物标志物分析可能对 OPSCC 中的特定患者具有预后价值。
